Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck Disease (KBD) patients

International Orthopaedics

Volumn 35, Issue 9, 2011, Pages 1409-1414

  Luo, Rui ^a   Liu, Gang ^a   Liu, Wei ^a   Pei, Fuxing ^a   Zhou, Zongke ^a   Li, Jian ^a   Shen, Bin ^a   Kang, Pengde ^a   Xie, Qibing ^a   Ma, Xin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; MELOXICAM; PARACETAMOL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; JOINT FUNCTION; JOINT STIFFNESS; KASHIN BECK DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARALLEL DESIGN; PHYSICAL CAPACITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HEALTH STATUS; HUMANS; JOINTS; KASHIN-BECK DISEASE; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PYRAZOLES; SULFONAMIDES; THIAZINES; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80655148045     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-010-1062-0     Document Type: Article

References (29)

1. Yang C, Niu C, Bodo M, Gabriel E, Notbohm H, Wolf E, Müller PK (1993) Fulvic acid supplementation and selenium deficiency disturb the structural integrity ofmouse skeletal tissue. An animal model to study the molecular defects of Kashin-Beck disease. Biochem J 289(Pt 3):829-835 (Pubitemid 23074971)
2. Wang Y, Yang Z, Gilula LA, Zhu C (1996) Kashin-Beck disease: radiographic appearance in the hands and wrists. Radiology 201:265-270 (Pubitemid 26314400)
3. Chasseur C, Suetens C, Nolard N, Begaux F, Haubruge E (1997) Fungal contamination in barley and Kashin-Beck disease in Tibet. Lancet 350:1074 (Pubitemid 27437861)
4. Haubruge E, Chasseur C, Debouck C, Begaux F, Suetens C, Mathieu F, Michel V, Gaspar C, Rooze M, Hinsenkamp M, Gillet P, Nolard N, Lognay G (2001) The prevalence ofmycotoxins in Kashin-Beck disease. Int Orthop 25:159-161
5. Moreno-Reyes R, Suetens C, Mathieu F, Begaux F, Zhu D, Rivera MT, Boelaert M, Nève J, Perlmutter N, Vanderpas J (1998) Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status. N Engl J Med 339:1112-1120 (Pubitemid 28465759)
6. Moreno-Reyes R, Mathieu F, Boelaert M, Begaux F, Suetens C, Rivera MT, Nève J, Perlmutter N, Vanderpas J (2003) Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. Am J Clin Nutr 78:137-144 (Pubitemid 39655259)
7. La Grange M, Mathieu F, Begaux F, Suetens C, Durand MC (2001) Kashin-Beck disease and drinking water in Central Tibet. Int Orthop 25:167-169 (Pubitemid 32606145)
8. Zhai SS, Kimbrough RD, Meng B, Han JY, Le Vois M, Hou X, Yin XN (1990) Kashin-Beck disease: a cross-sectional study in seven villages in the People's Republic of China. J Toxicol Environ Health 30:239-259 (Pubitemid 20269909)
9. Moerman J, Uyttendaele D, Van den Broecke W, Claessens H (1992) Kashin-Beck's disease. Acta Orthop Belg 58:227-230
10. Mathieu F, Begaux F, Lan ZY, Suetens C, Hinsenkamp M (1997) Clinical manifestations of Kashin-Beck disease in Nyemo Valley, Tibet. Int Orthop 21:151-156 (Pubitemid 27371114)
11. Hinsenkamp M, Ryppens F, Begaux F, Mathieu F, De Maertelaer V, Lepeire M, Haubruge E, Chasseur C, Stallenberg B (2001) The anatomical distribution of radiological abnormalities in Kashin-Beck disease in Tibet. Int Orthop 25:142-146 (Pubitemid 32606138)
12. Hinsenkamp M, Mathieu F, Claus W, Collard JF, de Maertelaer V (2009) Effects of physical environment on the evolution of Kashin-Beck disease in Tibet. Int Orthop 33:1085-1088
13. Liu FD, Wang ZL, Hinsenkamp M (1998) Osteotomy at the knee for advanced cases of Kashin-Beck disease. Int Orthop 22:87-91 (Pubitemid 28284594)
14. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833-1840 (Pubitemid 19037656)
15. Mathieu F, Suetens C, Begaux F, De Maertelaer V, Hinsenkamp M (2001) Effects ofphysical therapy on patients with Kashin-Beck disease in Tibet. Int Orthop 25:191-193 (Pubitemid 32606150)
16. Fitz Gerald GA, Patrono C (2001) The coxibs, selective inhibitors ofcyclooxygenase-2. N Engl J Med 345:433-442
17. Bensen WG, Fiechtner JJ, Mc Millen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS (1999) Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: arandomized controlledtrial. Mayo Clin Proc 74:1095-1105 (Pubitemid 30243242)
18. Williams GW, Ettlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, Zhao W, Geis GS (2000) Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol 6:65-74 (Pubitemid 30226944)
19. Mc Kenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS (2001) Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 30:11-18
20. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C (1997) Differential inhibition of human prostaglandin endoperoxide synthase-1 and-2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48:623-631 (Pubitemid 28055590)
21. Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G (1998) Differential inhibition of cyclooxygenases-1 and-2 by meloxicam and its 4'-isomer. Inflamm Res 47:270-276 (Pubitemid 28325586)
22. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for the medicalmanagementofosteoarthritis. Part I. Osteoarthritisofthehip. American Collegeof Rheumatology. Arthritis Rheum38:1535-1540
23. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 38:1541-1546
24. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR (1990) The effect ofprescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881-1884 (Pubitemid 20316533)
25. Salzman C (1995) Medication compliance in the elderly. J Clin Psychiatry 56(Suppl 1):18-22, discussion 23
26. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointes-tinal and platelet effects. Arthritis Rheum 41:1591-1602 (Pubitemid 28459917)
27. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255
28. Deeks JJ, Smith LA, Bradley MD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325:619
29. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325:624